|Articles|October 15, 2002
- BioPharm International-10-01-2002
- Volume 15
- Issue 10
FDA Launches Major CGMP Review
Author(s)Jill Wechsler
by Jill Wechsler Agency officials are reexamining manufacturing standards and plant inspection processes.
Advertisement
Articles in this issue
almost 23 years ago
Process Validation: How Much to Do and When to Do Italmost 23 years ago
Biotech Will Recover!almost 23 years ago
GMPs and Pharmaceutical Labelingalmost 23 years ago
Revolutionizing Biologics RegulationNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
